Lily Adelzadeh, MD
Dermatology · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 3 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
16 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Adelzadeh’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$42,554
Medicare paid this office $42,554 for 130 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 72 | $7,830 | $76 |
| Destruction of skin growth, 1-14 growths | 45 | $7,381 | $107 |
| Return visit (30+ min) | 30 | $4,554 | $103 |
| Destruction of precancer skin growth, 1 growth | 57 | $4,312 | $46 |
| Biopsy of related skin growth, first growth | 40 | $4,210 | $88 |
See all 9 services
| Short return visit (20+ min) | 72 | $7,830 | $76 |
| Destruction of skin growth, 1-14 growths | 45 | $7,381 | $107 |
| Return visit (30+ min) | 30 | $4,554 | $103 |
| Destruction of precancer skin growth, 1 growth | 57 | $4,312 | $46 |
| Biopsy of related skin growth, first growth | 40 | $4,210 | $88 |
| Destruction of precancer skin growth, 2-14 growths | 48 | $2,288 | $7 |
| New patient visit (45+ min) | 11 | $1,498 | $136 |
| New patient visit (30+ min) | 14 | $978 | $70 |
| Short return visit | 13 | $666 | $48 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 12 | More than 66% of doctors who do this |
| Removal of skin lesions | 134 | More than 77% of doctors who do this |
| Skin biopsy | 37 | More than 67% of doctors who do this |
Who their Medicare patients are
130 Original Medicare patients in 2024. Average age 74 · Women 63% · Health risk score 0.95. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Coronary heart disease 20% · Chronic kidney disease 18% · Cancer 18% · Diabetes 15% · Atrial fibrillation 11% · Heart failure 9% · Depression 9% · COPD 8%.
The office billed $80,881, Medicare allowed $59,499 and paid $42,554; for 795 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 130 | 795 | 74 | 0.95 | $80,881 | $42,554 |
| 2023 | 139 | 864 | 75 | 0.93 | $120,600 | $59,609 |
| 2022 | 93 | 478 | 76 | 0.98 | $67,355 | $33,767 |
| 2021 | 133 | 743 | 74 | 0.99 | $105,768 | $56,700 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 40 | $7,682 | $104 |
| Short return visit (20+ min) | 71 | $7,384 | $71 |
| Biopsy of related skin growth, first growth | 55 | $6,420 | $90 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 20 | $6,136 | $307 |
| Destruction of skin growth, 1-14 growths | 39 | $5,303 | $102 |
| Destruction of precancer skin growth, 1 growth | 60 | $4,680 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 42 | $2,008 | $7 |
| New patient visit (45+ min) | 15 | $1,701 | $113 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,588 | $122 |
| Biopsy of related skin growth, each additional growth | 19 | $1,179 | $51 |
| New patient visit (30+ min) | 11 | $901 | $82 |
2022: 7 services
| Destruction of skin growth, 1-14 growths | 34 | $4,265 | $102 |
| Short return visit (20+ min) | 43 | $4,177 | $76 |
| Return visit (30+ min) | 22 | $3,126 | $108 |
| Destruction of precancer skin growth, 1 growth | 32 | $1,888 | $45 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 11 | $1,558 | $104 |
| New patient visit (30+ min) | 16 | $1,454 | $91 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $871 | $7 |
2021: 13 services
| Return visit (30+ min) | 39 | $6,685 | $108 |
| Short return visit (20+ min) | 61 | $6,644 | $80 |
| Destruction of skin growth, 1-14 growths | 38 | $4,937 | $99 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $4,723 | $295 |
| Destruction of precancer skin growth, 1 growth | 58 | $4,086 | $48 |
| New patient visit (30+ min) | 30 | $2,635 | $88 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 17 | $2,482 | $118 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 15 | $1,647 | $110 |
| New patient visit (45+ min) | 14 | $1,568 | $112 |
| Destruction of precancer skin growth, 2-14 growths | 38 | $1,496 | $7 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $1,486 | $124 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 11 | $909 | $76 |
| Short return visit | 12 | $652 | $54 |
Drugs they prescribed that Part D paid
$21,984
Pharmacies billed $21,984 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 142) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
139 generic and fewer than 11 brand-name prescriptions · $21,984 in drug cost · 12 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 12 | $584 | $49 |
| Clindamycin Phosphate | 11 | $238 | $22 |
| Ketoconazole | 23 | $226 | $10 |
| Triamcinolone Acetonide | 20 | $83 | $4 |
Year by year
| 2024 | 142 | 61 | 0% (0) | None | $21,984 |
| 2023 | 137 | 59 | 0% (0) | None | $5,907 |
| 2022 | 57 | 31 | 0% (0) | None | $12,842 |
| 2021 | 148 | 50 | 0% (0) | None | $58,891 |
| 2020 | 111 | 37 | 0% (0) | None | $14,679 |
| 2019 | 70 | 24 | 0% (0) | None | $29,428 |
| 2018 | 53 | 23 | None | None | $32,179 |
| 2017 | 59 | 27 | 0% (0) | 20% | $70,898 |
| 2016 | 22 | None | 0% (0) | None | $1,165 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ketoconazole | 23 | $445 | $19 |
| Triamcinolone Acetonide | 23 | $242 | $11 |
| Doxycycline Hyclate | 11 | $172 | $16 |
| Prednisone | 13 | $108 | $8 |
2021: 4 drugs
| Ketoconazole | 12 | $260 | $22 |
| Triamcinolone Acetonide | 30 | $141 | $5 |
| Hydrocortisone | 12 | $66 | $5 |
| Hydroxyzine | 15 | $52 | $3 |
2020: 3 drugs
| Ketoconazole | 21 | $483 | $23 |
| Mupirocin | 11 | $139 | $13 |
| Triamcinolone Acetonide | 16 | $89 | $6 |
2019: 2 drugs
| Ketoconazole | 12 | $166 | $14 |
| Triamcinolone Acetonide | 12 | $140 | $12 |
2018: 1 drug
| Ketoconazole | 13 | $448 | $34 |
Money from drug and device companies
$259 in 2025
| 2025 | 6 | 10 | None | $259 |
| 2024 | 8 | 18 | None | $551 |
| 2023 | 4 | 15 | None | $346 |
| 2022 | 2 | 4 | None | $206 |
| 2021 | 1 | 1 | None | $71 |
| 2020 | 1 | 1 | None | $21 |
| 2019 | 4 | 5 | None | $211 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $85 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $56 | 2 payments
|
| LEO Pharma | Adbry | $47 | 2 payments
|
| Lilly USA | Taltz | $33 | 1 payment
|
| Abbvie | Skyrizi | $21 | 1 payment
|
| Galderma Laboratories L.P. | Nemluvio | $17 | 1 payment
|
See all 10 published payments
| LEO Pharma | Meals · 2025-09-04 | Anzupgo | $23 |
| Lilly USA | Meals · 2025-08-19 | Taltz | $33 |
| Galderma Laboratories L.P. | Meals · 2025-06-25 | Nemluvio | $17 |
| LEO Pharma | Meals · 2025-06-17 | Adbry | $23 |
| Janssen Biotech | Meals · 2025-05-29 | Tremfya | $33 |
| Regeneron Healthcare Solutions | Meals · 2025-05-16 | Dupixent | $36 |
| Janssen Biotech | Meals · 2025-03-25 | Tremfya | $31 |
| Janssen Biotech | Meals · 2025-02-18 | Tremfya | $22 |
| Abbvie | Meals · 2025-01-31 | Skyrizi | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-01-29 | Dupixent | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $551
| Janssen Biotech | Tremfya | $175 | 3 payments
|
| Abbvie | Skyrizi | $154 | 7 payments
|
| Novartis Pharmaceuticals | Cosentyx | $100 | 3 payments
|
| Incyte | Opzelura | $28 | 1 payment
|
| STRATA Skin Sciences | Xtrac | $27 | 1 payment
|
| LEO Pharma | Adbry | $24 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $23 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $20 | 1 payment
|
2023: $346
| AbbVie | Skyrizi | $144 | 6 payments
|
| Pfizer | Eucrisa | $114 | 5 payments
|
| Dermavant Sciences | Vtama | $51 | 2 payments
|
| Genzyme | Dupixent | $37 | 2 payments
|
2022: $206
| Stryker | Xpress Ent Dilation System | $153 | 1 payment
|
| Abbvie | Skyrizi | $53 | 3 payments
|
2021: $71
| AbbVie | Skyrizi | $71 | 1 payment
|
2020: $21
| VYNE Pharmaceuticals | Amzeeq | $21 | 1 payment
|
2019: $211
| Celgene | Otezla | $129 | 1 payment
|
| AbbVie | Humira | $44 | 2 payments
|
| Amgen | Enbrel | $20 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 88.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265852180
- Trained
- University of California, Geffen School of Medicine, 2014
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 2351 Clay St, Suite 380, San Francisco, CA, 94115
- NPI first listed
- 2014-04-17
- NPI last updated
- 2024-11-21
- NPI record certified
- 2024-11-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 48 Fenton St, Livermore, CA, 94550 · 2262 Camino Ramon Ste 200, San Ramon, CA, 94583
This office lists an electronic records connection.